PARIS--(BUSINESS WIRE)--Regulatory News:
ABIVAX (Paris:ABVX) (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today provides its planned financial calendar for 2017, which is set as follows:
|Wednesday March 15, 2017||Publication of 2016 Financial Statements|
|Friday April 28, 2017||Publication and Release of the Annual Financial Report|
|Friday June 23, 2017||Annual Shareholders Meeting|
|Wednesday September 20, 2017||Publication of Financial Statements as of June 30, 2017|
|Friday September 29, 2017||Publication and Release of 2017 Half Year Report|
All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (www.abivax.com/en).
About ABIVAX (www.abivax.com)
ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. ABIVAX leverages three technology platforms for drug discovery: an anti-viral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase II clinical trials for providing a functional cure for patients with HIV/AIDS. It is a first-in-class oral small anti-viral molecule which blocks HIV replication through a unique mechanism of action and also has a strong anti-inflammatory effect. In addition, ABIVAX is advancing a clinical stage immune enhancer as well as multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue), and several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX).
More information on the company is available at www.abivax.com.
Follow us on Twitter @ABIVAX_